Now showing 1 - 4 of 4
  • 2017-08-31Journal Article
    [["dc.bibliographiccitation.journal","Journal of cachexia, sarcopenia and muscle"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2019-07-09T11:43:39Z"],["dc.date.available","2019-07-09T11:43:39Z"],["dc.date.issued","2017-08-31"],["dc.identifier.doi","10.1002/jcsm.12230"],["dc.identifier.pmid","28857511"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14612"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58937"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2190-6009"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Considering technique of assessment and method for normalizing skeletal muscle mass."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC
  • 2017-11Journal Article
    [["dc.bibliographiccitation.firstpage","448"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","ESC heart failure"],["dc.bibliographiccitation.lastpage","457"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Dos Santos, Marcelo R."],["dc.contributor.author","Emami, Amir"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Bekfani, Tarek"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Lainscak, Mitja"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","von Haehling, Stephan"],["dc.date.accessioned","2019-07-09T11:44:42Z"],["dc.date.available","2019-07-09T11:44:42Z"],["dc.date.issued","2017-11"],["dc.description.abstract","AIMS: We aimed to assess determinants of anorexia, that is loss of appetite in patients with heart failure (HF) and aimed to further elucidate the association between anorexia, functional capacity, and outcomes in affected patients. METHODS AND RESULTS: We assessed anorexia status among 166 patients with HF (25 female, 66 ± 12 years) who participated in the Studies Investigating Co-morbidities Aggravating HF. Anorexia was assessed by a 6-point Likert scale (ranging from 0 to 5), wherein values ≥1 indicate anorexia. Functional capacity was assessed as peak oxygen uptake (peak VO2 ), 6 min walk test, and short physical performance battery test. A total of 57 patients (34%) reported any anorexia, and these patients showed lower values of peak VO2 , 6 min walk distance, and short physical performance battery score (all P < 0.05). Using multivariate analysis adjusting for clinically important factors, only high-sensitivity C-reactive protein [odds ratio (OR) 1.24, P = 0.04], use of loop diuretics (OR 5.76, P = 0.03), and the presence of cachexia (OR 2.53, P = 0.04) remained independent predictors of anorexia. A total of 22 patients (13%) died during a mean follow-up of 22.5 ± 5.1 months. Kaplan-Meier curves for cumulative survival showed that those patients with anorexia presented higher mortality (Log-rank test P = 0.03). CONCLUSIONS: Inflammation, use of loop diuretics, and cachexia are associated with an increased likelihood of anorexia in patients with HF, and patients with anorexia showed impaired functional capacity and poor outcomes."],["dc.identifier.doi","10.1002/ehf2.12209"],["dc.identifier.pmid","28960880"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14870"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59070"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation","info:eu-repo/grantAgreement/EC/FP7/241558/EU//SICA-HF"],["dc.relation.issn","2055-5822"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC
  • 2017-10Journal Article
    [["dc.bibliographiccitation.firstpage","851"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of cachexia, sarcopenia and muscle"],["dc.bibliographiccitation.lastpage","852"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Springer, Jochen"],["dc.date.accessioned","2019-07-09T11:44:34Z"],["dc.date.available","2019-07-09T11:44:34Z"],["dc.date.issued","2017-10"],["dc.description.abstract","not available"],["dc.identifier.doi","10.1002/jcsm.12229"],["dc.identifier.pmid","28849617"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14816"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59035"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2190-6009"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Is cardiac wasting accompanied by skeletal muscle loss in breast cancer patients receiving anticancer treatment?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC
  • 2017Journal Article
    [["dc.bibliographiccitation.artnumber","e00037"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle ‐ Clinical Reports"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Springer, Jochen"],["dc.contributor.author","Haehling, Stephan von"],["dc.date.accessioned","2019-07-10T08:12:05Z"],["dc.date.available","2019-07-10T08:12:05Z"],["dc.date.issued","2017"],["dc.description.abstract","Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is highly expressed in skeletal muscle, was first described in 1997. It has been known that loss of myostatin function induces an increase in muscle mass in mice, cow, dogs and humans. Therefore, myostatin and its receptor have emerged as a therapeutic target for loss of skeletal muscle such as sarcopenia and cachexia, as well as muscular dystrophies. At the molecular level, myostatin binds to and activates the activin receptor IIB (ActRIIB)/Alk 4/5 complex. Therapeutic approaches therefore are being taken both pre‐clinically and clinically to inhibit the myostatin signaling pathway. Several myostatin inhibitors , including myostatin antibodies, anti‐myostatin peptibody, activin A antibody, soluble (decoy) forms of ActRIIB (ActRⅡB‐Fc), anti‐myostatin adnectin, ActRⅡB antibody have been tested in the last decade. The aim of this review is to present the current knowledge of several myostatin inhibitors as a therapeutic approach for patients with loss of skeletal muscle."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2017"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14833"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60859"],["dc.language.iso","de"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.issn","2190-6009"],["dc.rights","CC BY 4.0"],["dc.rights.access","openAccess"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.subject","Myostatin; Myostatin inhibitor; Muscle wasting; Sarcopenia; Cachexia;Neuromuscular dystrophy"],["dc.subject.ddc","610"],["dc.title","Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]
    Details